Perrigo Company plc $PRGO Shares Bought by Readystate Asset Management LP

Readystate Asset Management LP lifted its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 50.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 274,684 shares of the company’s stock after buying an additional 92,058 shares during the period. Readystate Asset Management LP’s holdings in Perrigo were worth $2,950,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after acquiring an additional 1,014 shares during the period. Geneos Wealth Management Inc. boosted its holdings in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares in the last quarter. UMB Bank n.a. grew its position in Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares during the period. Meeder Asset Management Inc. purchased a new position in Perrigo in the fourth quarter valued at about $28,000. Finally, CWM LLC lifted its position in shares of Perrigo by 230.0% during the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after acquiring an additional 1,527 shares during the period. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PRGO has been the subject of several research analyst reports. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Perrigo currently has a consensus rating of “Hold” and an average target price of $19.33.

Perrigo Stock Up 1.2%

Shares of NYSE:PRGO opened at $10.27 on Wednesday. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. The company has a market capitalization of $1.42 billion, a P/E ratio of -0.78, a P/E/G ratio of 1.20 and a beta of 0.51. Perrigo Company plc has a 52-week low of $9.23 and a 52-week high of $28.22. The stock’s fifty day simple moving average is $10.59 and its 200-day simple moving average is $11.71.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The company had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the firm earned $0.60 EPS. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities research analysts forecast that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.